Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02047474
Other study ID # 1306012255
Secondary ID NCI-2013-0234913
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 25, 2014
Est. completion date December 2026

Study information

Verified date November 2023
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.


Description:

PRIMARY OBJECTIVES: I. To determine the progression-free survival in patients with resectable non-metastatic pancreatic cancer treated with peri-operative modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, oxaliplatin (mFOLFIRINOX). SECONDARY OBJECTIVES: I. Determine overall survival. II. Determine objective response rate after neoadjuvant mFOLFIRINOX. TERTIARY OBJECTIVES: I. Compare R0 resection rate and pathologic stage with institutional historical controls who did not receive neoadjuvant therapy. II. Correlate early metabolic response, determined by changes in glucose metabolism using positron emission tomography (PET) scanning, with pathologic response, R0 resection, and pathologic stage. III. Correlate early metabolic response, determined by changes in glucose metabolism using PET scanning, with progression-free and overall survival. IV. Correlate pre-operative response of CA19-9 with progression-free and overall survival. V. Collect and bank serial serum and plasma specimens from subjects for future correlative biomarker studies. VI. Collect and bank tumor tissue from subjects prior to treatment (from the diagnostic endoscopic ultrasonography [EUS]-guided biopsy) and after treatment with six cycles of FOLFIRINOX (from the surgical specimen) for future correlative biomarker studies. OUTLINE: NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin intravenously (IV) over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection. ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months for 3 years, every 6 months for 2 years, and then annually thereafter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 46
Est. completion date December 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologic or cytologic documentation of pancreatic adenocarcinoma - Resectable pancreatic adenocarcinoma disease as defined as follows: - No evidence of extrapancreatic disease by cross sectional imaging, PET scan, or laparoscopy, including nodal involvement beyond the peripancreatic tissues and/or distant metastases; - No evidence of tumor extension to superior mesenteric artery, hepatic artery, celiac axis, aorta, or inferior vena cava, and no evidence of occlusion or encasement of the superior mesenteric vein or superior mesenteric vein/portal vein confluence, as assessed by computed tomography (CT) using pancreatic protocol (or magnetic resonance imaging [MRI] in patients who cannot undergo CT) and EUS - No prior treatment (chemotherapy, biological therapy, or radiotherapy) for resectable pancreatic cancer - No prior treatment with oxaliplatin, irinotecan (irinotecan hydrochloride), fluorouracil or capecitabine - Patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are eligible - There is no evidence of the second malignancy at the time of study entry - > 4 weeks since major surgery - No other concurrent anticancer therapy - Eastern Cooperative Oncology Group (ECOG) performance status: 0-1 - No other malignancy within past five years except basal cell carcinoma of the skin, cervical carcinoma in situ, or non-metastatic prostate cancer - Paraffin block or slides must be available - Adequate organ function - No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung - No >= grade 2 sensory peripheral neuropathy - No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease - No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment - No history of chronic diarrhea - Not pregnant and not nursing - No other medical condition or reason that, in the opinion of the investigator, would preclude study participation - Absolute neutrophil count >= 1,500/uL - Platelet count >= 100,000/uL - Hemoglobin >= 9 g/dL - Creatinine < 1.5 X upper limit of normal (ULN) or - Estimated glomerular filtration rate (GFR) > 30 ml/min - Bilirubin =< 1.5 X ULN - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN - Negative pregnancy test in women of childbearing age

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
oxaliplatin
Given IV
leucovorin calcium
Given IV
irinotecan hydrochloride
Given IV
fluorouracil
Given IV
Procedure:
therapeutic conventional surgery
Undergo surgical resection
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Smilow Cancer Hospital at Fairfield Fairfield Connecticut
United States Smilow Cancer Hospital at Guilford Guilford Connecticut
United States Smilow Cancer Hospital at St. Francis Hospital Hartford Connecticut
United States Yale University New Haven Connecticut
United States Smilow Cancer Hospital at North Haven North Haven Connecticut
United States Smilow Cancer Hospital at Orange Orange Connecticut
United States Smilow Cancer Hospital at Torrington Torrington Connecticut
United States Smilow Cancer Hospital at Trumbull Trumbull Connecticut
United States Smilow Cancer Hospital at Waterbury Waterbury Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival rate Evaluated using a one-sided 0.10-alpha level exact test. Summarized using Kaplan-Meier curves At 12 months
Secondary Overall survival Summarized using Kaplan-Meier curves. Up to 5 years
Secondary Objective response rate Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT02178436 - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Phase 2
Completed NCT02153450 - Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Early Phase 1
Completed NCT01821612 - Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Early Phase 1
Terminated NCT01739439 - Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Phase 1
Completed NCT01537107 - Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Withdrawn NCT02048943 - Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Phase 1
Completed NCT00031694 - Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT01473940 - Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Phase 1
Withdrawn NCT01741597 - Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Phase 1
Completed NCT01839981 - CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 1
Completed NCT00085371 - Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Phase 2
Completed NCT01234935 - Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Phase 2
Completed NCT01666730 - Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Phase 2
Terminated NCT00416793 - Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Phase 2
Completed NCT00052689 - Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer Phase 2
Completed NCT01924260 - Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Phase 1
Completed NCT00981162 - Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Phase 1
Completed NCT01893294 - Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer Phase 1